胰腺癌免疫抑制性肿瘤微环境研究综述

doi:10.3969/j.issn.1674-8115.2021.08.018

摘要/Abstract

摘要：

胰腺癌是一种高度恶性的肿瘤，早期诊断困难且缺乏有效的治疗方法，导致预后极差。胰腺癌肿瘤微环境包含肿瘤细胞、免疫细胞、基质细胞、细胞外基质以及多种可溶性分子；其中，细胞外成分包括基质成分和可溶性因子等，在肿瘤的发生、发展、侵袭和转移过程中发挥重要作用。胰腺癌微环境中具有显著的免疫细胞浸润，以免疫抑制为突出特征。肿瘤细胞一方面编辑免疫系统，使其无法被免疫系统识别；另一方面招募和激活各种免疫抑制性细胞如胰腺星状细胞、髓系来源抑制细胞、肿瘤相关巨噬细胞和调节性T细胞等，进而分泌免疫抑制性分子，影响抗肿瘤免疫细胞的功能，抑制宿主的抗肿瘤免疫反应，造成肿瘤的免疫逃逸，促进肿瘤的发展转移。该文讨论胰腺癌肿瘤微环境各种免疫抑制成分的作用机制，并总结胰腺癌免疫治疗的最新成果，以期为胰腺癌免疫抑制性肿瘤微环境的研究以及胰腺癌的免疫治疗提供新的思路。

关键词: 胰腺癌, 肿瘤微环境, 免疫抑制性, 免疫治疗

Abstract:

Pancreatic cancer is a highly malignant tumor. The difficulty of early diagnosis and scarcity of effective clinical treatment strategies lead to poor prognosis. Tumor microenvironment (TME) of pancreatic cancer is composed of tumor cells, immune cells, stromal cells, extracellular matrix and soluble factors. TME plays an important role in the development, progression, invasion and metastasis of tumors. The pancreatic cancer microenvironment has significant immune cell infiltration, which is highly immunosuppressive. On the one hand, tumor cells edit the immune system so that cancer cells cannot be recognized by the immune system; on the other hand, they can recruit and activate various immunosuppressive cells such as pancreatic stellate cells, myeloid-derived inhibitory cells, tumor-associated macrophages, regulatory T cells and so on. These immunosuppressive cells can secrete immunosuppressive molecules, affect the function of anti-tumor immune cells, inhibit the host′s anti-tumor immune response, lead to tumor immune escape, and promote tumor development and metastasis. In this review, the mechanisms and effects of these immunosuppressive components are discussed and the updated results of immunotherapy on pancreatic cancer are studied, which may provide novel insights on TME and immunotherapy of pancreatic cancer.

Key words: pancreatic cancer, tumor microenvironment (TME), immunosuppression, immunotherapy

中图分类号:

R735.9

李静威, 王俐文, 蒋玲曦, 詹茜, 陈皓, 沈柏用. 胰腺癌免疫抑制性肿瘤微环境研究综述[J]. 上海交通大学学报(医学版), 2021, 41(8): 1103-1108.

Jing-wei LI, Li-wen WANG, Ling-xi JIANG, Qian ZHAN, Hao CHEN, Bai-yong SHEN. Review of immunosuppressive tumor microenvironment of pancreatic cancer[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1103-1108.

参考文献 50

1	Fan JQ, Wang MF, Chen HL, et al. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma[J]. Mol Cancer, 2020, 19(1): 32.
2	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
3	Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer[J]. Lancet, 2016, 388(10039):73-85.
4	Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment[J]. Clin Cancer Res, 2012, 18(16): 4266-4276.
5	叶辰, Zheng L, 原春辉. 胰腺癌免疫微环境及免疫治疗的前景与展望 [J]. 中华外科杂志, 2019, 57(1): 10-15.
6	Zheng L, Xue J, Jaffee EM, et al. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma[J]. Gastroenterology, 2013, 144(6): 1230-1240.
7	卢军, 刘乔飞, 周立,等. 胰腺癌抑制性免疫微环境研究进展 [J]. 中华实验外科杂志, 2018, 35(8): 1393-1398.
8	Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts[J]. Cancer Discov, 2019, 9(8): 1102-1123.
9	Neesse A, Algül H, Tuveson DA, et al. Stromal biology and therapy in pancreatic cancer: a changing paradigm[J]. Gut, 2015, 64(9): 1476-1484.
10	Binenbaum Y, Na'ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma[J]. Drug Resist Updat, 2015, 23: 55-68.
11	von Ahrens D, Bhagat TD, Nagrath D, et al. The role of stromal cancer-associated fibroblasts in pancreatic cancer[J]. J Hematol Oncol, 2017, 10(1): 76.
12	Liu QF, Liao Q, Zhao YP. Chemotherapy and tumor microenvironment of pancreatic cancer[J]. Cancer Cell Int, 2017, 17(1): 1-17.
13	Zhang YF, Jiang SH, Hu LP, et al. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy[J]. Chin Clin Oncol, 2019, 8(2): 18.
14	Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer[J]. PNAS, 2013, 110(50): 20212-20217.
15	Hartmann N, Giese NA, Giese T, et al. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer[J]. Clin Cancer Res, 2014, 20(13): 3422-3433.
16	Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival[J]. Cancer Cell, 2014, 25(6): 719-734.
17	徐敏, 王兴鹏. 胰腺星状细胞的发现及其意义 [J]. 胰腺病学, 2003, 3(z1): 25-27.
18	Allam A, Thomsen AR, Gothwal M, et al. Pancreatic stellate cells in pancreatic cancer: in focus[J]. Pancreatology, 2017, 17(4): 514-522.
19	Hamada S, Masamune A, Yoshida N, et al. IL-6/STAT3 plays a regulatory role in the interaction between pancreatic stellate cells and cancer cells[J]. Dig Dis Sci, 2016, 61(6): 1561-1571.
20	Tang D, Yuan Z, Xue X, et al. High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer[J]. Int J Cancer, 2012, 130(10): 2337-2348.
21	Dineen SP, Lynn KD, Holloway SE, et al. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice[J]. Cancer Res, 2008, 68(11): 4340-4346.
22	Han X, Li Y, Xu Y, et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem[J]. Nat Commun, 2018, 9(1): 3390.
23	Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018, 19(2): 108-119.
24	Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b⁺/Gr-1⁺/CD31⁺ myeloid progenitor capable of activating or suppressing CD8⁺ T cells[J]. Blood, 2000, 96(12): 3838-3846.
25	Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion[J]. Cancer Res, 2007, 67(19): 9518-9527.
26	Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth[J]. Cancer Immunol Immunother, 2012, 61(9): 1373-1385.
27	Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients[J]. J Immunol Res, 2014, 2014: 879897.
28	Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-174.
29	Huang B, Pan PY, Li Q, et al. Gr-1⁺CD115⁺ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host [J]. Cancer Res, 2006, 66(2): 1123-1131.
30	杨黎, 张毅. 肿瘤相关巨噬细胞研究进展[J]. 中国免疫学杂志, 2020, 36(2): 129-135.
31	蒋维香, 林彦俊, 岳建明. CD163⁺、CD204⁺巨噬细胞在胰腺癌组织中的浸润及临床意义[J]. 国际消化病杂志, 2019, 39(6): 436-439.
32	Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 [J]. J Exp Med, 2009, 206(6): 1327-1337.
33	Wang D, Yang L, Yue D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion[J]. Cancer Lett, 2019, 452: 244-253.
34	Li L, Yang L, Wang L, et al. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages[J]. Int J Cancer, 2016, 139(10): 2261-2269.
35	Zhang Y, Velez-Delgado A, Mathew E, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer[J]. Gut, 2017, 66(1): 124-136.
36	Kaneda MM, Cappello P, Nguyen AV, et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression [J]. Cancer Discov, 2016, 6(8):870-885.
37	黄德良, 朱新海, 盛良翮. 胰腺癌患者外周血中调节性T细胞和辅助性T细胞17的表达及其血清相关因子的检测[J]. 广东医学, 2017, 38(12): 1874-1876.
38	王秀超, 李鑫, 郝继辉. 调节性T细胞参与胰腺癌免疫微环境重塑的基础与转化研究进展[J]. 中国肿瘤临床, 2018, 45(18): 964-968.
39	Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance[J]. Immunity, 2007, 27(4): 635-646.
40	Bauer CA, Kim EY, Marangoni F, et al. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction[J]. J Clin Invest, 2014, 124(6): 2425-2440.
41	Jang JE, Hajdu CH, Liot C, et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer[J]. Cell Rep, 2017, 20(3): 558-571.
42	Azuma T, Takahashi T, Kunisato A, et al. Human CD4⁺CD25⁺regulatory T cells suppress NKT cell functions[J]. Cancer Res, 2003, 63(15): 4516-4520.
43	Soares KC, Rucki AA, Kim V, et al. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner [J]. Oncotarget, 2015, 6(40): 43005-43015.
44	Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer[J]. Cancer Discov, 2016, 6(3): 270-285.
45	Daley D, Zambirinis CP, Seifert L, et al. γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation [J]. Cell, 2016, 166(6): 1485-1499.e15.
46	Zamanakou M, Germenis AE, Karanikas V. Tumor immune escape mediated by indoleamine 2,3-dioxygenase [J]. Immunol Lett, 2007,111(2):69-75.
47	刘文增, 胡渊, 张彩. 胰腺癌的肿瘤微环境及其免疫治疗研究进展 [J]. 中国免疫学杂志, 2018, 34(12): 1901-1906.
48	Wu Q, Tian Y, Zhang J, et al. Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma[J]. Oncotarget, 2017, 8(60): 102721-102738.
49	Liang X, Sun J, Wu H, et al. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay[J]. Diagn Pathol, 2018, 13(1): 5.
50	Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma[J]. J Immunother, 2010, 33(8): 828-833.

[1]	凌徐心仪, 张瑶, 钟华. 非小细胞肺癌免疫治疗获益人群筛选的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(8): 1114-1119.
[2]	那迪娜·帕尔哈提null, 严妍, 车千纪, 罗菁, 刘鑫男, 李斌. 嵌合抗原受体T细胞疗法在胶质母细胞瘤中的应用与展望[J]. 上海交通大学学报(医学版), 2021, 41(7): 982-986.
[3]	马韵芳, 潘丽娜, 李圳, 高蓓莉, 胡家安, 徐志红. 司美替尼下调KRAS G12V突变型非小细胞肺癌细胞PD-L1水平的探索性研究[J]. 上海交通大学学报(医学版), 2021, 41(6): 741-748.
[4]	杨鹿笛, 王高明, 胡仁豪, 蒋小华, 崔然. 生物信息学方法筛选胰腺癌进展相关的核心基因[J]. 上海交通大学学报(医学版), 2021, 41(5): 571-578.
[5]	顾琦晟, 张米粒, 曹灿, 李继坤. 基于TCGA数据库分析胃癌可变剪接与肿瘤免疫的关系[J]. 上海交通大学学报(医学版), 2021, 41(4): 448-458.
[6]	刘梦珂, 纪濛濛, 程林, 黄金艳, 孙晓建, 赵维莅, 王黎. 黄芩苷抗肿瘤作用机制的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(2): 246-250.
[7]	潘德燊1, 2，李登1，邵怡1. 白细胞介素 -11对肿瘤促进作用的研究进展[J]. 上海交通大学学报（医学版）, 2020, 40(4): 548-.
[8]	赵伟光，刘志宏. 肿瘤相关成纤维细胞调控肿瘤免疫炎症微环境的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(09): 1288-1293.
[9]	何春明，尹航，郑佳杰，唐健，傅于捷，赵晓菁. 肺癌免疫治疗：免疫抑制细胞和肺内免疫[J]. 上海交通大学学报(医学版), 2020, 40(08): 1137-1142.
[10]	刘洁，仇晓春. 乳腺肿瘤干细胞研究热点及趋势分析[J]. 上海交通大学学报(医学版), 2020, 40(07): 881-888.
[11]	戴飞，魏瑾瑾，汤欣玥，陈峥，蔺林. 舌下含服免疫治疗对效应性T细胞和调节性T细胞功能的影响[J]. 上海交通大学学报(医学版), 2020, 40(05): 626-632.
[12]	梁雨，江明杰，田聆. 前列腺素 E 2重塑胰腺肿瘤微环境的作用机制研究进展[J]. 上海交通大学学报（医学版）, 2019, 39(8): 923-.
[13]	吴广喜，石学银，何斌. 肺炎克雷伯菌疫苗的研制进展[J]. 上海交通大学学报（医学版）, 2018, 38(4): 458-.
[14]	李夏伊，郑磊贞. 程序性死亡蛋白 1/程序性死亡配体 1抑制剂在晚期胃癌治疗中的应用[J]. 上海交通大学学报（医学版）, 2018, 38(10): 1259-.
[15]	夏莉，王月英 . 嵌合抗原受体 T 细胞疗法及其在血液肿瘤免疫治疗中的应用[J]. 上海交通大学学报（医学版）, 2017, 37(6): 822-.